Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Net Income Loss of -$162.34 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -91.1% in Net Income Loss from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Dianthus Therapeutics, Inc. /DE/'s Net Income Loss has declined by 1,621.3%.
- Historical annual values: Fiscal year 2025: -$162.34 million | Fiscal year 2024: -$84.97 million | Fiscal year 2023: -$43.56 million | Fiscal year 2022: -$28.48 million | Fiscal year 2021: -$71.14 million | Fiscal year 2020: -$74.94 million | Fiscal year 2019: -$76.77 million | Fiscal year 2018: -$57.52 million | Fiscal year 2017: -$35.49 million | Fiscal year 2016: -$9.43 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: